TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Mesoblast Soars on Stem-Cell Treatment Data
HEALTH

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

PRESS RELEASES

Lexicon Pharmaceuticals To Participate In The 39th Annual J.P. Morgan Healthcare Conference

PRESS RELEASES

Lexicon Pharmaceuticals Announces Commencement Of Dosing In Phase 2 Clinical Study Of LX9211 In Post-Herpetic Neuralgia

PRESS RELEASES

Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience

PRESS RELEASES

Lexicon Announces Offering Of Common Stock

PRESS RELEASES

Lexicon Pharmaceuticals Receives Fast Track Designation From The FDA For LX9211 For Diabetic Peripheral Neuropathic Pain

PRESS RELEASES

Results From SOLOIST And SCORED Outcomes Studies Presented At Late-Breaking Science Session Of American Heart Association Scientific Sessions And Published In The New England Journal Of Medicine

PRESS RELEASES

Lexicon Pharmaceuticals To Participate In The Stifel 2020 Virtual Healthcare Conference

PRESS RELEASES

Lexicon Pharmaceuticals To Host Third Quarter 2020 Financial Results Conference Call And Webcast On October 29, 2020

PRESS RELEASES

Lexicon Pharmaceuticals Reaches Agreements To Exchange Convertible Notes, Reduce Outstanding Indebtedness

PRESS RELEASES

Lexicon Pharmaceuticals Completes The Sale Of XERMELO To TerSera Therapeutics

PRESS RELEASES

Lexicon Pharmaceuticals Announces Commencement Of Patient Dosing In RELIEF-DPN-1 Phase 2 Clinical Study Of LX9211 In Patients With Diabetic Peripheral Neuropathic Pain

PRESS RELEASES

Lexicon Pharmaceuticals To Participate In The Citi 15ᵗʰ Annual BioPharma Virtual Conference And The Wells Fargo 2020 Virtual Healthcare Conference

PRESS RELEASES

GTCR And TerSera Therapeutics Announce Acquisition Of Xermelo

PRESS RELEASES

Lexicon Realigns Business Around Research And Development Assets, With Focus On Phase 2 LX9211 Neuropathic Pain Program

PRESS RELEASES

Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics For The Sale Of XERMELO

PRESS RELEASES

Lexicon Pharmaceuticals To Host Second Quarter 2020 Financial Results Conference Call And Webcast On July 30, 2020

PRESS RELEASES

Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies In Type 2 Diabetes

PRESS RELEASES

Lexicon Pharmaceuticals Announces Poster Presentations At The Virtual Cholangiocarcinoma Foundation Annual Conference

PRESS RELEASES

Lexicon Pharmaceuticals Presents Clinical Data At 80th American Diabetes Association Scientific Sessions

PRESS RELEASES

Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

PRESS RELEASES

Lexicon Pharmaceuticals Announces Preclinical Efficacy Data On Telotristat Ethyl's Antiproliferative Effects Against Various Cancer Cell Lines

PRESS RELEASES

Lexicon Pharmaceuticals To Host First Quarter 2020 Financial Results Conference Call And Webcast On April 27, 2020

PRESS RELEASES

LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM

PRESS RELEASES

LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL'S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME